CRC. Edward Rose

C. Edward Rose

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


C. Edward Rose has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Borna Mehrad

    Department of Medicine University of Florida College of Medicine Gainesville Florida USA

    1 shared publication
  • Brett A. Strieter

    Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Va

    1 shared publication
  • Ling Liu

    Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Va

    1 shared publication
  • Marie D. Burdick

    Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Va

    1 shared publication
  • Michael Joseph George Peach

    Department of Chemistry, Lancaster University, Lancaster, LA1 4YB, UK

    1 shared publication
  • Robert M. Carey

    Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia Health System, Charlottesville

    1 shared publication

Latest Publications

  • Number, activation, and differentiation of circulating fibrocytes correlate with asthma severity

    by Ryan Shipe, Marie D. Burdick, Brett A. Strieter, Ling Liu, Yun Michael Shim, Sun-Sang Sung, W. Gerald Teague, Borna Mehrad, Robert M. Strieter, C. Edward Rose


  • Significant Involvement of CCL2 (MCP‐1) in Inflammatory Disorders of the Lung

    by C. Edward Rose, Sung‐Sang J. Sung, Shu Man Fu

    Mounting evidence suggests that CCL2 (MCP‐1) and its hematopoietic cell receptor CC chemokine receptor 2 (CCR2) are involved in inflammatory disorders of the lung. In animal models of allergic asthma, idiopathic pulmonary fibrosis (IPF), and bronchiolitis obliterans syndrome (BOS), CCL2 expression and protein production are increased and the disease process is attenuated by CCL2 immunoneutralization. Mechanisms by which CCL2 may be acting include recruitment of regulatory and effector leukocytes; stimulation of histamine or leukotriene release from mast cells or basophils; induction of fibroblast production of transforming growth factor‐β (TGF‐β) and procollagen; and enhancement of Th2 polarization. Recently, polymorphism for CCL2 has been described with increased cytokine‐induced release of CCL2 by monocytes and increased risk of allergic asthma. These studies identify potentially important roles for CCL2 in these lung inflammatory disorders. While CCL2 inhibition in patients with acute respiratory distress syndrome (ARDS) may be hazardous by interfering with defense against bacteremia, future studies are needed to determine if CCL2/CCR2 antagonism will offer breakthrough therapy for patients with allergic asthma, IPF, or BOS, and to confirm the hypothesis that CCL2 polymorphism places patients at greater risk for these disorders.


  • Role of Angiotensin II in Renal Vasoconstriction with Acute Hypoxemia and Hypercapnic Acidosis in Conscious Dogs

    by C. Edward Rose, Michael J. Peach, Robert M. Carey

    To evaluate the role ofrenin-angiotensin in the renal vasoconstriction with combined acute hypoxemia and hypercapnic acidosis preceded by acute hypoxemia, we studied eight conscious mongrel uninephrectomized dogs with chronic renal catheters and controlled sodium intake (80 mEq/24 h ± 4 days). The animals were studied during combined acute hypoxemia and hypercapnic acidosis (PaO2 34 ± 1 mm Hg, PaCO2 57 ± 1 mm Hg, pH 7.20 ± 0.01) preceded by 80 min of acute hypoxemia (PaO234 ± 1 mm Hg) during: (a) intrarenal infusion of vehicle (n = 8); or (b) intrarenal administration of the angiotensin II antagonist [Sar1, Ala8]-AII, 70 ng kg−1 min−1 (n = 8). The combination of acute hypoxemia and hypercapnic acidosis resulted in diminished effective renal plasma flow and increased renal vascular resistance during intrarenal vehicle infusion. Intrarenal [Sar1, Ala8]-AII did not abolish the renal vasoconstriction in the initial 20 min of this combined blood gas derangement but resulted in a more prompt return of the renal vascular variables toward control levels with continuation of the blood gas derangement for an additional 20 min, suggesting a role for angiotensin in renal vasoconstriction. These observations suggest that while rennin—angiotensin may not mediate the initial renal vasoconstriction in the first 20 min of combined acute hypoxemia and hypercapnic acidosis, in uninephrectomized conscious dogs, it attenuates the spontaneous recovery of renal hemodynamic variables to baseline as the blood gas derangement continues.